{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"An Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy.","item":"https:\/\/www.regionalcancercare.org\/trials\/an-open-label-multicenter-single-arm-phase-2-study-of-single-agent-mosunetuzumab-btct4465a-ro7030816-for-the-treatment-of-patients-with-newly-diagnosed-follicular-lymphoma-in-need-of-systemic-th\/#breadcrumbitem"}]}